357 related articles for article (PubMed ID: 33513913)
1. RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death.
Kim SY; Park S; Lee SW; Lee JH; Lee ES; Kim M; Kim Y; Kang JS; Chung CH; Moon JS; Lee EY
Cells; 2021 Jan; 10(2):. PubMed ID: 33513913
[TBL] [Abstract][Full Text] [Related]
2. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.
Sanchez-Niño MD; Sanz AB; Carrasco S; Saleem MA; Mathieson PW; Valdivielso JM; Ruiz-Ortega M; Egido J; Ortiz A
Nephrol Dial Transplant; 2011 Jun; 26(6):1797-802. PubMed ID: 20504837
[TBL] [Abstract][Full Text] [Related]
3. Lyso-Gb3 activates Notch1 in human podocytes.
Sanchez-Niño MD; Carpio D; Sanz AB; Ruiz-Ortega M; Mezzano S; Ortiz A
Hum Mol Genet; 2015 Oct; 24(20):5720-32. PubMed ID: 26206887
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide.
Jeon YJ; Jung N; Park JW; Park HY; Jung SC
PLoS One; 2015; 10(8):e0136442. PubMed ID: 26291612
[TBL] [Abstract][Full Text] [Related]
5. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.
Choi L; Vernon J; Kopach O; Minett MS; Mills K; Clayton PT; Meert T; Wood JN
Neurosci Lett; 2015 May; 594():163-8. PubMed ID: 25697597
[TBL] [Abstract][Full Text] [Related]
6. High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway.
Xu Y; Gao H; Hu Y; Fang Y; Qi C; Huang J; Cai X; Wu H; Ding X; Zhang Z
Exp Cell Res; 2019 Sep; 382(2):111463. PubMed ID: 31247189
[TBL] [Abstract][Full Text] [Related]
7. Curcumin Blocks High Glucose-Induced Podocyte Injury via RIPK3-Dependent Pathway.
Chung H; Lee SW; Hyun M; Kim SY; Cho HG; Lee ES; Kang JS; Chung CH; Lee EY
Front Cell Dev Biol; 2022; 10():800574. PubMed ID: 35706905
[TBL] [Abstract][Full Text] [Related]
8. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts.
Choi JY; Shin MY; Suh SH; Park S
Biochem Biophys Res Commun; 2015 Dec; 468(4):883-8. PubMed ID: 26592662
[TBL] [Abstract][Full Text] [Related]
9. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
10. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
11. Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy.
Trimarchi H; Ortiz A; Sánchez-Niño MD
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33203029
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
[TBL] [Abstract][Full Text] [Related]
14. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
15. Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.
Jabbarzadeh-Tabrizi S; Boutin M; Day TS; Taroua M; Schiffmann R; Auray-Blais C; Shen JS
J Lipid Res; 2020 Nov; 61(11):1410-1423. PubMed ID: 32868283
[TBL] [Abstract][Full Text] [Related]
16. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
17. Lyso-globotriaosylsphingosine induces endothelial dysfunction
Hwang AR; Park S; Woo CH
Korean J Physiol Pharmacol; 2023 May; 27(3):231-240. PubMed ID: 37078297
[TBL] [Abstract][Full Text] [Related]
18. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
Nowak A; Mechtler T; Kasper DC; Desnick RJ
Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
[TBL] [Abstract][Full Text] [Related]
19. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
20. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.
Niemann M; Rolfs A; Störk S; Bijnens B; Breunig F; Beer M; Ertl G; Wanner C; Weidemann F
Circ Cardiovasc Genet; 2014 Feb; 7(1):8-16. PubMed ID: 24395922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
